University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > HIV Meds Updates
Elvitegravir Approved as an Independent Medication
Related Resources
ARV Profiles
ARV Charts & Tables
Opportunistic Infections

Elvitegravir is an HIV integrase inhibitor that requires pharmacokinetic enhancement with cobicistat or ritonavir. Since 2012, it has been available in a coformulation with cobicistat, tenofovir, and emtricitabine (Stribild) for treatment-naive adults. This month, the FDA approved elvitegravir as an independent medication, for use in in combination with a ritonavir-boosted protease inhibitor (and other ARVs) in treatment-experienced adults. Its brand name is Vitekta.

It is dosed once daily, with the specific dosage determined by the coadministered ritonavir-boosted PI:

Elvitegravir 85 mg QD with: atazanavir 300 mg QD + ritonavir 100 mg QD or lopinavir/ritonavir 400/100 mg BID
Elvitegravir 150 mg QD with: darunavir 600 mg BID + ritonavir 100 mg BID, fosamprenavir 700 mg BID + ritonavir 100 mg BID, or tipranavir 500 mg BID + ritonavir 200 mg BID

Elvitegravir should not be used with cobicistat, except in the coformulation with cobicistat/tenofovir/emtricitabine (Stribild); thus, it is not recommended with cobicistat-boosted PIs. It also is not recommended with PIs other than those indicated above.

It should be taken with food.

Further information is available in the prescribing information at Drugs@FDA.